Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Enzymatic Reduction . These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN110004119B discloses a thermostable epsilon-ketoester reductase mutant enabling efficient synthesis of (R)-alpha-lipoic acid precursors with reduced catalyst loading and enhanced stability.
Patent CN111172124A reveals a novel carbonyl reductase mutant enabling high-concentration synthesis. Discover cost-effective supply chain solutions for this key pharma intermediate.
Patent CN111705068A reveals a novel ketoreductase route for high-purity (R)-EHB, offering significant cost reduction and scalability for antibiotic intermediates.
Novel fission yeast reductase enables efficient D-pantolactone synthesis. Reduces cost and improves supply chain reliability for pharmaceutical and feed additive manufacturers.
Patent CN113621663A reveals a novel enzymatic route for Ezetimibe, offering high purity and streamlined manufacturing for reliable pharmaceutical intermediate suppliers.
Patent CN118388570A reveals a novel enzymatic-chemical hybrid route for UDCA intermediates. Achieve superior selectivity and safety for pharmaceutical manufacturing.
Novel enzymatic route for Telaprevir intermediate ensures high purity and scalable production. Reliable supplier for pharmaceutical intermediates with cost-effective manufacturing.
Patent CN106701698B reveals high-efficiency SsCR enzyme for chiral alcohol synthesis. Achieves 99.9% ee and 500mmol/L substrate concentration for scalable manufacturing.
Discover the enzymatic synthesis of 3 beta 7 beta dihydroxy 5 alpha H UDCA isomer. A cost-effective, high-purity pharmaceutical intermediate solution.
Patent CN100567497C details a novel two-phase enzymatic route for high-purity chiral 2-butanol. This method offers significant supply chain stability and cost reduction advantages.
Patent CN109503542B reveals a green synthesis for Atorvastatin intermediates, eliminating toxic cyanides and reducing EHS risks for reliable API manufacturing.
Discover the green synthesis of Rosuvastatin Calcium intermediates via novel organometallic routes. Reduce EHS risks and optimize supply chain reliability with our advanced manufacturing capabilities.
Novel enzymatic route for 2-deoxy-2,2-difluoro-3,5-dibenzoyl-D-ribofuranose offers high yield and purity, replacing hazardous hydrogenation for reliable supply.
Patent CN116024187B enables enzymatic synthesis. Offers cost reduction and supply chain reliability for pharmaceutical intermediates manufacturing.
Patent CN105624214A reveals high-efficiency enzymatic synthesis. Offers supply chain stability and cost reduction in agrochemical intermediate manufacturing without heavy metals.
Novel amide-mediated route for Bempedoic Acid reduces steps and improves purity. Ideal for reliable pharmaceutical intermediate suppliers seeking cost-effective scale-up.
Patent CN104860980A introduces enzymatic synthesis with high optical purity and mild conditions, enabling cost reduction and reliable supply for pharmaceutical manufacturing.